Takeda Pharmaceuticals America, Inc. (TPA) and Affymax, Inc. have entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the U.S. Omontys is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia in adult dialysis patients with chronic kidney disease (CKD) in the U.S.
The agreement allows DSI Renal to purchase Omontys for use within its organization and provides for discounts and rebates on the product, subject to certain requirements. DSI Renal plans to initially evaluate Omontys in selected centers, and will then evaluate the potential to expand to additional centers. Financial terms were not disclosed.
“We look forward to working with DSI Renal as they integrate Omontys into their dialysis centers,” said John Orwin, chief executive officer of Affymax. “With this agreement, we now have supply agreements in place with five out of the six medium-sized dialysis organizations in the U.S.”